Verve Therapeutics, Inc.

NasdaqGS:VERV Rapport sur les actions

Capitalisation boursière : US$991.5m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Verve Therapeutics Croissance future

Future contrôle des critères 0/6

Le chiffre d'affaires et le bénéfice de Verve Therapeutics devraient diminuer respectivement de 26.4% et de 15.7% par an. Le BPA devrait diminuer de 7.5% par an. Le rendement des capitaux propres devrait être de -93% dans 3 ans.

Informations clés

-15.7%

Taux de croissance des bénéfices

-7.53%

Taux de croissance du BPA

Biotechs croissance des bénéfices25.3%
Taux de croissance des recettes-26.4%
Rendement futur des capitaux propres-92.96%
Couverture par les analystes

Good

Dernière mise à jour04 Jul 2025

Mises à jour récentes de la croissance future

Recent updates

Seeking Alpha • Jun 17

Verve Therapeutics' Lifeline: Eli Lilly's $1.3 Billion Bet On Cardiovascular Gene Therapy (Upgrade)

Summary Eli Lilly's $1.3B offer for Verve Therapeutics is a lifeline, providing a 70%+ premium and a solid exit for Verve investors. VERV struggled as a standalone due to tough gene therapy commercialization and competition from established cardiovascular treatments like statins and PCSK9 inhibitors. For LLY, the acquisition diversifies its pipeline and positions it for future innovation in chronic disease, despite high risk and uncertain payoff. The deal is mutually beneficial: Verve gets a strong exit, while Eli Lilly makes a speculative, forward-looking bet with its abundant cash reserves. Read the full article on Seeking Alpha
Article d’analyse • May 28

Verve Therapeutics, Inc. (NASDAQ:VERV) Shares May Have Slumped 26% But Getting In Cheap Is Still Unlikely

Unfortunately for some shareholders, the Verve Therapeutics, Inc. ( NASDAQ:VERV ) share price has dived 26% in the last...
Article d’analyse • May 19

News Flash: Analysts Just Made An Incredible Upgrade To Their Verve Therapeutics, Inc. (NASDAQ:VERV) Forecasts

Verve Therapeutics, Inc. ( NASDAQ:VERV ) shareholders will have a reason to smile today, with the analysts making...
Seeking Alpha • Apr 16

Verve Therapeutics: FDA Fast Track And Eli Lilly Partnership Upgrade It To A 'Buy'

Summary VERV’s VERVE-102 showed an impressive 69% LDL-C reduction in its early Phase 1b data. Also, LLY may opt into VERVE-102’s development later this year, which would help VERV by covering one-third of the R&D costs. Similarly, VERV’s pipeline includes VERVE-201 for HoFH and refractory hypercholesterolemia, as well as VERVE-301 in collaboration with Lilly. And from a valuation perspective, the shares are cheaper than the first time I covered it. All while making great progress with its pipeline. So, ultimately, I think VERV remains a high-risk, long-term play in gene editing. But its risk-reward profile now seems to justify a “Buy” rating. Read the full article on Seeking Alpha
Seeking Alpha • Mar 25

Verve Therapeutics: HeFH Treatment Program Of VERVE-102 Remains On Track With 2025 Catalysts

Summary Company received FDA IND clearance for VERVE-102 to treat HeFH, adding new trial sites in the United States. The switch to the Gal-NAc LNP delivery system aims to improve safety, avoiding clinical abnormalities observed with VERVE-101. Key upcoming catalysts include initial phase 1b Heart-2 data in Q2 2025, final dose-escalation data, and potential Eli Lilly opt-in for PCSK9 inhibitor program in the 2nd half of 2025. Atherosclerotic Cardiovascular Disease, in the 7 Major Markets, is expected to reach $30.6 billion by 2035. Read the full article on Seeking Alpha
Seeking Alpha • Feb 28

Verve Therapeutics: Key Data Catalysts, Major Share Price Volatility In Play In Q2

Summary Verve Therapeutics' stock remains a "Buy" despite recent setbacks, including the retirement of its Chief Medical Officer and the termination of a collaboration with Vertex. Verve's gene-editing programs aim to transform cardiovascular disease treatment by permanently lowering cholesterol through a one-time intravenous infusion, offering significant therapeutic and commercial potential. The upcoming data readout for Verve-102 in 2025 is crucial; success could attract Eli Lilly's partnership, while failure may question the entire base editing approach. Despite leadership changes and challenges, Verve's innovative approach and potential for groundbreaking treatments justify a high-risk, high-reward investment strategy. Read the full article on Seeking Alpha
Article d’analyse • Dec 08

Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Aug 30

Verve Therapeutics: An In Vivo Gene Editing 'Moon Shot' For Your Portfolio

Summary Verve Therapeutics aims to revolutionize cardiovascular disease treatment with single-course gene editing, despite facing significant challenges and setbacks in clinical trials. The company's lead assets, VERVE-101 and VERVE-102, target the PCSK9 gene to lower LDL-C levels, but safety issues have hindered progress. Verve-102, using a different delivery technology, is now the focus, with initial data expected in 1H25, presenting a crucial milestone for investors. Partnerships with Eli Lilly, Beam Therapeutics, and Vertex offer potential financial support and validation, but Verve remains a high-risk, high-reward investment. Read the full article on Seeking Alpha
Article d’analyse • Aug 10

Earnings Release: Here's Why Analysts Cut Their Verve Therapeutics, Inc. (NASDAQ:VERV) Price Target To US$25.78

As you might know, Verve Therapeutics, Inc. ( NASDAQ:VERV ) just kicked off its latest second-quarter results with some...
Article d’analyse • Jul 12

We're Not Very Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Seeking Alpha • Jun 13

Why Verve Therapeutics Deserves A Spot On Your Watchlist

Summary Verve Therapeutics focuses on gene editing technology for one-dose therapies to reduce lipid levels related to ASCVD. VERV's pipeline includes therapies targeting genes like PCSK9, ANGPTL3, and LPA to lower ASCVD risk. Verve's leading programs, VERVE-101 and VERVE-102, target heterozygous familial hypercholesterolemia (HeFH), with VERVE-101 in clinical trials and VERVE-102 in the IND-enabling stage. Financially, Verve has a strong cash position, with $606.3 million in liquidity and a cash runway of approximately 3.5 years. VERV's research is in the early stages, making it a speculative investment, but it is worth adding to a watchlist as research progresses. Read the full article on Seeking Alpha
Article d’analyse • May 14

Broker Revenue Forecasts For Verve Therapeutics, Inc. (NASDAQ:VERV) Are Surging Higher

Verve Therapeutics, Inc. ( NASDAQ:VERV ) shareholders will have a reason to smile today, with the analysts making...
Article d’analyse • May 12

The Verve Therapeutics, Inc. (NASDAQ:VERV) First-Quarter Results Are Out And Analysts Have Published New Forecasts

As you might know, Verve Therapeutics, Inc. ( NASDAQ:VERV ) just kicked off its latest first-quarter results with some...
Seeking Alpha • Apr 03

Verve Therapeutics Stock Remains A Hold After VERVE-101 Enrollment Pause

Summary Enrollment paused in the Verve Therapeutics' phase 1b heart-1 study, using VERVE-101 for the treatment of patients with heterozygous familial hypercholesterolemia after a Grade 3 adverse event. Despite VERVE-101 setback, the ability to move forward with another PCSK9 inhibitor known as VERVE-102 where the phase 1b heart-2 study is expected to begin any day now in Q2 2024. VERVE-102 could be a major change in structure because it has two distinct features compared to its predecessor, which are a different ionizable lipid and the GalNAc delivery system. Partnership with Eli Lilly remains in place for now, despite VERVE-101 enrollment being paused. Read the full article on Seeking Alpha
Article d’analyse • Feb 28

Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Feb 13

Verve's Proof-Of-Concept Data Doesn't Inspire Confidence

Summary Verve Therapeutics aims to revolutionize cardiovascular disease treatment with gene therapy. Recent VERVE-101 data shows LDL-C reduction comparable to existing drugs but with serious adverse events in two patients, raising safety concerns. Verve's financials show a solid runway with ~$600 million in liquid assets after a recent capital infusion, but ongoing and future trials will demand substantial funding. Recommendation: Sell. Despite proof-of-concept and a one-time treatment appeal, safety concerns and competitive landscape challenge its long-term valuation. Read the full article on Seeking Alpha
Seeking Alpha • Jan 14

Vectoring In On Verve Therapeutics

Summary Verve Therapeutics aims to revolutionize treatment for cardiovascular disease through in vivo gene therapy using base editing technology. Their lead candidate, VERVE-101, has shown promising results in reducing LDL-C levels in preclinical studies. Verve has partnerships with Beam Therapeutics, Eli Lilly, and Vertex Pharmaceuticals, and analysts have a positive outlook on the company. A full investment analysis around Verve Therapeutics stock is presented in the paragraphs below. Read the full article on Seeking Alpha
Article d’analyse • Jun 07

Here's Why We're Not Too Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Article d’analyse • Feb 24

Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Article d’analyse • Nov 09

We Think Verve Therapeutics (NASDAQ:VERV) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Sep 20

Verve Therapeutics: Cathie Wood Adds To ARKK

Summary ARKG component added to flagship fund. Meaningful position would top 7% of outstanding shares. Company fits usual pattern with large losses and cash burn.

Prévisions de croissance des bénéfices et des revenus

NasdaqGS:VERV - Estimations futures des analystes et données financières antérieures (USD Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
12/31/202722-302-235-2356
12/31/202623-275-228-2078
12/31/202542-229-231-1908
3/31/202560-181-147-142N/A
12/31/202432-199-161-158N/A
9/30/202424-197-162-158N/A
6/30/202421-193-134-130N/A
3/31/202416-197-150-144N/A
12/31/202312-200-159-150N/A
9/30/20238-193-154-142N/A
6/30/20235-192-173-159N/A
3/31/20233-179-152-138N/A
12/31/20222-157-136-122N/A
9/30/20221-148-127-117N/A
6/30/2022N/A-125-117-110N/A
3/31/2022N/A-137-102-96N/A
12/31/2021N/A-120-82-78N/A
9/30/2021N/A-113-69-65N/A
6/30/2021N/A-99-54-50N/A
3/31/2021N/A-53-47-44N/A
12/31/2020N/A-46-39-35N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: VERV devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: VERV devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: VERV devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Les revenus de VERV devraient diminuer au cours des 3 prochaines années ( -26.4% par an).

Croissance élevée des revenus: Les revenus de VERV devraient diminuer au cours des 3 prochaines années ( -26.4% par an).

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: VERV devrait être non rentable dans 3 ans.

Découvrir les entreprises en croissance

7D

1Y

7D

1Y

7D

1Y

Analyse de l'entreprise et données financières

DonnéesDernière mise à jour (heure UTC)
Analyse de l'entreprise2025/07/24 08:43
Cours de l'action en fin de journée2025/07/24 00:00
Les revenus2025/03/31
Revenus annuels2024/12/31

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

PaquetDonnéesCadre temporelExemple de source américaine *
Finances de l'entreprise10 ans
  • Compte de résultat
  • Tableau des flux de trésorerie
  • Bilan
Estimations consensuelles des analystes+3 ans
  • Prévisions financières
  • Objectifs de prix des analystes
Prix du marché30 ans
  • Cours des actions
  • Dividendes, scissions et actions
Propriété10 ans
  • Actionnaires principaux
  • Délits d'initiés
Gestion10 ans
  • L'équipe dirigeante
  • Conseil d'administration
Principaux développements10 ans
  • Annonces de l'entreprise

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.

Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

Verve Therapeutics, Inc. est couverte par 4 analystes. 8 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

AnalysteInstitution
Andrea NewkirkGoldman Sachs
Andrea NewkirkGoldman Sachs
Mitchell KapoorH.C. Wainwright & Co.